Bajaj HealthCare Limited (BAJAJHCARE.BO)
INR 516.0
(-1.29%)
INR 516.0
(-1.29%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.73 Billion INR | -29.69% |
| 2022 | 6.73 Billion INR | -0.97% |
| 2021 | 6.79 Billion INR | 3.68% |
| 2020 | 6.55 Billion INR | 60.83% |
| 2019 | 4.07 Billion INR | 26.14% |
| 2018 | 3.23 Billion INR | 12.61% |
| 2017 | 2.87 Billion INR | 40.34% |
| 2016 | 2.04 Billion INR | -8.2% |
| 2015 | 2.22 Billion INR | 2.08% |
| 2014 | 2.18 Billion INR | 6.54% |
| 2013 | 2.04 Billion INR | 19.98% |
| 2012 | 1.7 Billion INR | 20.69% |
| 2011 | 1.41 Billion INR | 18.05% |
| 2010 | 1.19 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.32 Billion INR | -1.23% |
| 2023 Q4 | 1.33 Billion INR | 23.33% |
| 2023 Q1 | 1.29 Billion INR | -18.12% |
| 2023 FY | 4.73 Billion INR | -29.69% |
| 2023 Q2 | 1.01 Billion INR | -21.99% |
| 2023 Q3 | 1.08 Billion INR | 7.27% |
| 2022 Q3 | 1.41 Billion INR | -27.36% |
| 2022 Q4 | 1.58 Billion INR | 11.67% |
| 2022 FY | 6.73 Billion INR | -0.97% |
| 2022 Q2 | 1.95 Billion INR | 19.25% |
| 2022 Q1 | 1.63 Billion INR | -6.43% |
| 2021 Q1 | 1.85 Billion INR | 41.77% |
| 2021 Q3 | 1.67 Billion INR | 11.04% |
| 2021 FY | 6.79 Billion INR | 3.68% |
| 2021 Q4 | 1.75 Billion INR | 4.46% |
| 2021 Q2 | 1.5 Billion INR | -18.73% |
| 2020 Q2 | 2.06 Billion INR | 47.77% |
| 2020 FY | 6.55 Billion INR | 60.83% |
| 2020 Q3 | 1.78 Billion INR | -13.7% |
| 2020 Q4 | 1.3 Billion INR | -26.55% |
| 2020 Q1 | 1.39 Billion INR | 106.39% |
| 2019 Q3 | 992.72 Million INR | -1.27% |
| 2019 Q1 | 916.93 Million INR | 1.26% |
| 2019 FY | 4.07 Billion INR | 26.14% |
| 2019 Q4 | 677.5 Million INR | -31.75% |
| 2019 Q2 | 1 Billion INR | 9.65% |
| 2018 Q1 | 1.89 Billion INR | 112.08% |
| 2018 Q4 | 905.54 Million INR | -0.0% |
| 2018 FY | 3.23 Billion INR | 12.61% |
| 2018 Q3 | 905.54 Million INR | -4.21% |
| 2018 Q2 | 945.32 Million INR | -50.0% |
| 2017 FY | 2.87 Billion INR | 40.34% |
| 2017 Q2 | 744.06 Million INR | 0.0% |
| 2017 Q1 | 744.06 Million INR | 26.4% |
| 2017 Q4 | 891.48 Million INR | 0.0% |
| 2017 Q3 | 891.48 Million INR | 19.81% |
| 2016 Q4 | 588.63 Million INR | 0.0% |
| 2016 FY | 2.04 Billion INR | -8.2% |
| 2016 Q2 | 564.63 Million INR | 0.0% |
| 2016 Q1 | 564.63 Million INR | 14.23% |
| 2016 Q3 | 588.63 Million INR | 4.25% |
| 2015 Q1 | 622.72 Million INR | 0.0% |
| 2015 Q2 | 622.72 Million INR | 0.0% |
| 2015 Q3 | 482 Million INR | -22.6% |
| 2015 Q4 | 494.29 Million INR | 2.55% |
| 2015 FY | 2.22 Billion INR | 2.08% |
| 2014 FY | 2.18 Billion INR | 6.54% |
| 2013 FY | 2.04 Billion INR | 19.98% |
| 2012 FY | 1.7 Billion INR | 20.69% |
| 2011 FY | 1.41 Billion INR | 18.05% |
| 2010 FY | 1.19 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alkem Laboratories Limited | 126.67 Billion INR | 96.263% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -12.389% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 92.254% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 63.458% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 98.351% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -1082.501% |
| Eris Lifesciences Limited | 20.09 Billion INR | 76.437% |
| FDC Limited | 19.42 Billion INR | 75.634% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 79.265% |
| Ipca Laboratories Limited | 76.22 Billion INR | 93.789% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -126.839% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -838.921% |
| Laurus Labs Limited | 50.01 Billion INR | 90.535% |
| Lupin Limited | 200.1 Billion INR | 97.634% |
| Medicamen Biotech Limited | 1.79 Billion INR | -164.028% |
| Medico Remedies Limited | 1.44 Billion INR | -226.674% |
| Megasoft Limited | 373.95 Million INR | -1165.982% |
| NATCO Pharma Limited | 40.02 Billion INR | 88.17% |
| Piramal Pharma Limited | 81.71 Billion INR | 94.206% |
| Sigachi Industries Limited | 3.98 Billion INR | -18.664% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 61.772% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.024% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 54.971% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -82.615% |
| Themis Medicare Limited | 3.81 Billion INR | -24.009% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 95.536% |
| Valiant Laboratories Limited | 1.82 Billion INR | -160.038% |
| Wanbury Limited | 5.75 Billion INR | 17.759% |
| Windlas Biotech Limited | 6.3 Billion INR | 24.968% |
| ZIM Laboratories Limited | 3.67 Billion INR | -28.848% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 97.511% |
| Ajanta Pharma Limited | 42.08 Billion INR | 88.751% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 63.04% |
| Achyut Healthcare Limited | 61.36 Million INR | -7614.284% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -353.748% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -526.668% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 73.924% |
| Alpa Laboratories Limited | 1.08 Billion INR | -335.371% |
| Gufic Biosciences Limited | 8.06 Billion INR | 41.312% |
| Ind-Swift Limited | 5.02 Billion INR | 5.782% |
| Indoco Remedies Limited | 17.89 Billion INR | 73.544% |
| Hester Biosciences Limited | 3.04 Billion INR | -55.45% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 38.537% |
| RPG Life Sciences Limited | 5.82 Billion INR | 18.664% |
| Mankind Pharma Limited | 103.34 Billion INR | 95.419% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 95.992% |
| Unichem Laboratories Limited | 16.57 Billion INR | 71.436% |
| Bal Pharma Limited | 3.39 Billion INR | -39.561% |
| Strides Pharma Science Limited | 40.51 Billion INR | 88.314% |
| Venus Remedies Limited | 5.91 Billion INR | 19.956% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 92.937% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.304% |
| Divi's Laboratories Limited | 78.45 Billion INR | 93.965% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 71.889% |
| Shilpa Medicare Limited | 11.51 Billion INR | 58.891% |
| Aarti Drugs Limited | 25.28 Billion INR | 81.277% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 77.658% |
| Suven Life Sciences Limited | 116.92 Million INR | -3948.764% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 86.412% |
| Hikal Limited | 17.84 Billion INR | 73.472% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 58.878% |
| Sequent Scientific Limited | 13.69 Billion INR | 65.437% |
| Novartis India Limited | 3.35 Billion INR | -41.289% |
| Granules India Limited | 45.06 Billion INR | 89.494% |
| Wockhardt Limited | 27.89 Billion INR | 83.026% |
| Brooks Laboratories Limited | 794.86 Million INR | -495.598% |
| Neuland Laboratories Limited | 15.58 Billion INR | 69.625% |
| Morepen Laboratories Limited | 17.01 Billion INR | 72.183% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -206.672% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -28.439% |